内容概要：染色体核型分析是遗传病诊断、产前筛查与诊断、不孕不育病因排查、血液系统恶性肿瘤分 型及实体瘤遗传学检测领域的金标准核心技术，具备不可替代的临床价值，近年来，在优生优育理念全 面普及、高龄产妇群体持续扩大、婚检与孕检流程不断规范化的背景下，产前诊断相关需求呈现稳步增 长趋势，同时，血液科、肿瘤科诊疗技术的迭代升级，推动肿瘤染色体异常检测从科研层面逐步落地为 临床常规检测项目，成为肿瘤靶向治疗方案制定与预后评估的重要依据，此外，在生殖健康领域，反复 流产、生殖发育异常等问题的病因筛查，也高度依赖染色体核型分析系统，其临床刚需始终保持稳定且 逐步攀升的态势，据统计，2025年我国染色体核型分析系统市场规模达19670万元，同比增长18.6%， 其中，细胞收获仪约占19.9%，制片染色机约占9.7%，显微图像扫描仪约占49.4%，核型分析软件约占 21.0%。 相关企业：赛默飞世尔科技（中国）有限公司、徕卡显微系统（上海）贸易有限公司、杭州德适生物科 技股份有限公司、中科伊和智能医疗科技（广西）有限公司、中科伊和智能医疗科技（佛山）有限公 司、致慧医疗器械（浙江）有限公司、郑州中普医疗器械有限公司、长沙远安 ...

Group 1 - The China Securities Regulatory Commission has issued a notice regarding the overseas issuance and domestic unlisted shares "full circulation" registration for Hangzhou Deshi Biotechnology Co., Ltd. [1] - Deshi Biotechnology plans to issue no more than 31.04 million overseas listed ordinary shares and will list on the Hong Kong Stock Exchange [1] - A total of 27 shareholders of the company intend to convert their combined 80.88 million domestic unlisted shares into overseas listed shares for circulation on the Hong Kong Stock Exchange [1] Group 2 - Deshi Biotechnology is a leading enterprise in the field of medical imaging AI and medical imaging equipment, with a global market presence [2] - The company has developed a diversified matrix of intelligent equipment and supporting products based on its self-developed general medical imaging base model iMedImage™, including systems for chromosome karyotype analysis and automatic cell imaging [2] - In 2024, Deshi Biotechnology achieved a market share of 30.6% in the chromosome karyotype analysis field in China, ranking first and breaking the long-standing monopoly of imported brands [2] - The company has established a customer base covering over 400 medical care centers and institutions nationwide, gaining widespread market recognition [2] - In 2025, Deshi Biotechnology was selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog" due to its technological innovation and clinical value [2] - The company aims to continue providing standardized intelligent imaging equipment, model-as-a-service (MaaS) cloud platforms, and localized self-training solutions to enhance the efficiency, accuracy, and accessibility of medical imaging diagnosis [2]